Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Lifecore Biomedical (LFCR) over the last 17 years, with May 2025 value amounting to -$6.4 million.

  • Lifecore Biomedical's Cash from Investing Activities rose 22.71% to -$2.1 million in Q2 2025 from the same period last year, while for May 2025 it was -$6.4 million, marking a year-over-year increase of 65.13%. This contributed to the annual value of -$6.4 million for FY2025, which is 65.13% up from last year.
  • According to the latest figures from FY2025, Lifecore Biomedical's Cash from Investing Activities is -$6.4 million, which was up 65.13% from -$18.4 million recorded in FY2024.
  • Lifecore Biomedical's Cash from Investing Activities' 5-year high stood at $80.0 million during FY2022, with a 5-year trough of -$18.4 million in FY2024.
  • In the last 3 years, Lifecore Biomedical's Cash from Investing Activities had a median value of -$6.4 million in 2025 and averaged -$9.9 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first spiked by 749.57% in 2022, then slumped by 282.35% in 2024.
  • Lifecore Biomedical's Cash from Investing Activities (Yearly) stood at -$12.3 million in 2021, then skyrocketed by 749.57% to $80.0 million in 2022, then crashed by 106.02% to -$4.8 million in 2023, then slumped by 282.35% to -$18.4 million in 2024, then skyrocketed by 65.13% to -$6.4 million in 2025.